Gestational Age-Specific Reference Ranges for the sFlt-1/PlGF Immunoassay Ratio in Twin Pregnancies
Por:
De La Calle, M, Delgado, JL, Verlohren, S, Escudero, AI, Bartha, JL, Campillos, JM, De La Cruz, AA, Chantraine, F, Hernandez, JAG, Herraiz, I, Llurba, E, Kurka, H, Guo, G, Sillman, J, Hund, M, Marin, AP
Publicada:
1 abr 2021
Ahead of Print:
1 mar 2021
Resumen:
Objective: Establish reference ranges for the Elecsys (R) soluble fms-like tyrosine kinase-1 (sFlt-1)/placental growth factor (PlGF) immunoassay ratio in twin pregnancies. Methods: Data analyzed were from 3 prospective studies: Prediction of Short-Term Outcome in Pregnant Women with Suspected Preeclampsia (PE) (PROGNOSIS), Study of Early-onset PE in Spain (STEPS), and a multicenter case-control study. Median, 5th, and 95th percentiles for sFlt-1, PlGF, and the sFlt-1/PlGF ratios were determined for normal twin pregnancies for 7 gestational windows and compared with the previous data for singleton pregnancies. Results: The reference range analysis included 269 women with normal twin pregnancies. Before 29 weeks' gestation, median, 5th, and 95th percentiles for sFlt-1/PlGF ratios did not differ between twin and singleton pregnancies. From 29 weeks' gestation to delivery, median, 5th, and 95th percentiles for sFlt-1/PlGF ratios were substantially higher in twin versus singleton pregnancies. sFlt-1 values were higher in women with twin pregnancies across all gestational windows. PlGF values were similar or higher in twin versus singleton pregnancies; PlGF concentrations increased from 10 weeks + 0 days to 28 weeks + 6 days' gestation. Conclusions: Reference ranges for the sFlt-1/PlGF ratio are similar in women with twin and singleton pregnancies until 29 weeks' gestation but appear higher in twin pregnancies thereafter.
Filiaciones:
De La Calle, M:
Hosp Univ La Paz, Div Obstet & Maternal & Fetal Med, Madrid, Spain
Delgado, JL:
Univ Murcia, Dept Gynecol & Obstet, Murcia, Spain
IMIB Arrixaca, Murcia, Spain
Verlohren, S:
Charite, Dept Obstet, Berlin, Germany
Escudero, AI:
Hosp Univ Cent Asturias, Dept Obstet & Gynaecol, Oviedo, Spain
Bartha, JL:
Hosp Univ La Paz, Div Obstet & Maternal & Fetal Med, Madrid, Spain
Campillos, JM:
Hosp Univ Miguel Servet, Dept Obstet, Zaragoza, Spain
De La Cruz, AA:
Hosp Gen Univ Gregorio Maranon, Dept Gynecol & Obstet, Madrid, Spain
Chantraine, F:
Ctr Hosp Univ Liege, Dept Obstet & Gynecol, Site CHR Citadelle, Liege, Belgium
Hernandez, JAG:
Hosp Univ Materno Infantil Canarias, Dept Obstet & Gynecol, Gran Canaria, Spain
Herraiz, I:
Univ Complutense Madrid, Hosp Univ Octubre 12, Inst Invest Hosp Octubre Imas12 12, Dept Obstet & Gynaecol,Fetal Med Unit SAMID, Madrid, Spain
Llurba, E:
St Pau Univ Hosp, Obstet & Gynaecol Dept, High Risk Unit, Barcelona, Spain
St Pau Univ Hosp, Biomed Res Inst St Pau IIB St Pau, Barcelona, Spain
Univ Autonoma Barcelona, Sch Med, Barcelona, Spain
Inst Hlth Carlos III, Maternal & Child Hlth & Dev Network SAMID RD12 00, Madrid, Spain
Kurka, H:
Roche Diagnost GmbH, Biostat & Data Management CPS, Penzberg, Germany
Guo, G:
Roche Diagnost Operat Inc, Biostat & Data Management CPS, Indianapolis, IN USA
Sillman, J:
Roche Diagnost Int Ltd, Centralised & Point Care Solut, Rotkreuz, Switzerland
Hund, M:
Roche Diagnost Int Ltd, Centralised & Point Care Solut, Rotkreuz, Switzerland
Marin, AP:
Hosp Univ & Politecn La Fe, Dept Obstet & Gynecol, Avda F Abril Martorell 106 Torre F,3A Planta, ES-46026 Valencia, Spain
Green Published, hybrid
|